Lates News

Roche Pharmaceuticals (RHHBY) reported positive results from a late-stage trial of its breast cancer drug combination, including its new breast cancer drug, giredestrant. The trial met its primary endpoint showing a significant improvement in progression-free survival, leading to a 1.5% increase in Roche's stock price.